Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Featured News

    ChAd3 Vaccine Effective Against Ebola

    By Global Biodefense StaffSeptember 15, 2014
    Ebola virus in Democratic Republic of Congo
    Image courtesy of NIAID
    Share
    Facebook LinkedIn Reddit Email

    One shot of an experimental vaccine made from two Ebola virus gene segments incorporated into a chimpanzee cold virus vector, called chimp adenovirus type 3 (ChAd3), protected all macaque monkeys exposed to high levels of Ebola virus 5 weeks after inoculation, reports the National Institutes of Health (NIH) scientists and their collaborators.

    The ability of the ChAd3 Ebola virus vaccine to elicit rapid protection in monkeys is notable as the world health community battles an ongoing Ebola virus disease outbreak in West Africa. While the protective effects of the single shot waned over time, two out of four inoculated animals were protected when challenged with Ebola virus 10 months after vaccination.

    The research team, headed by Nancy J. Sullivan, Ph.D., of the National Institute of Allergy and Infectious Diseases Vaccine Research Center, also demonstrated increased levels of durable protection using an additional vaccine.

    They inoculated four macaques first with the ChAd3 Ebola vaccine, then 8 weeks later with a booster vaccine containing Ebola virus gene segments incorporated into a different vector (a poxvirus). Ten months after the initial inoculation, four out of four animals that received both shots were fully protected from infection with high doses of Ebola virus, demonstrating that the prime-boost regimen resulted in durable protection.

    The research team included scientists from Okairos, a Swiss-Italian biotechnology company now part of GlaxoSmithKline, and the U.S. Army Medical Research Institute of Infectious Diseases. The experimental ChAd3 Ebola vaccine used in these non-human primate studies is the same one currently being tested in an early-stage human clinical trial at the NIH in Bethesda, Maryland.

    Read more at Nature Medicine: Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.

    Adenovirus Ebola Emerging Threats Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleHarvard Funded for Paper-Based Biodefense Diagnostic
    Next Article Racing Ahead of Disease Outbreaks: $12M in Grants Awarded

    Related Stories

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    The Basics on the Nipah Virus Outbreak in India

    September 19, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    NIAID Seeks to Improve Computational Models of Influenza Immunity

    September 15, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.